Menu
Search Clinical Trials
Back to Search Results
Recruitment Complete
Astellas Study ID
015K-CL-CNA3

A Study to Assess Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Astellas Study ID
015K-CL-CNA3
Clinicaltrials.gov ID
NCT03660059
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
CTR20181199
Get more information

Study summary

The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in patients with rheumatoid arthritis (RA) who had an inadequate response or intolerance to MTX, as measured by the American College of Rheumatology (ACR) 20 response rate at Week 24.

This study will also evaluate the pharmacokinetics and safety of ASP015K as well as efficacy and safety of long-term treatment with ASP015K (52 weeks).

Additional Study Details

Phase
Phase 3
Product
peficitinib hydrobromide
Product
Peficitinib
Plaebo
Disease-modifying antirheumatic drugs (DMARDs)
Type
Interventional
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
385
Show Additional Study Details

Study documents

Plain Language Summary
Available Language(s): English, Spanish
Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) who Had an Inadequate Response or Intolerance to Methotrexate (MTX)? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site CN00069
    Jining, China
    Contact Us
    Completed
    Site CN00067
    Xining, China
    Contact Us
    Completed
    Site TW00025
    Taipei, Taiwan, Province of China
    Contact Us
    Active, not recruiting
    Site CN00071
    Guangdong, China
    Contact Us
    Completed
    Site TW00026
    Taipei, Taiwan, Province of China
    Contact Us
    Active, not recruiting
    Site CN00062
    Tianjin, China
    Contact Us
    Completed
    Site CN00053
    Sichuan, China
    Contact Us
    Active, not recruiting
    Site CN00076
    Chenzhou, China
    Contact Us
    Completed
    Site CN00065
    Xuzhou, China
    Contact Us
    Active, not recruiting
    Site CN00016
    Guangzhou, China
    Contact Us
    Completed
    Site KR00036
    Incheon, Republic of Korea
    Contact Us
    Completed
    Site CN00046
    Kunming, China
    Contact Us
    Active, not recruiting
    Site CN00050
    Bengbu, China
    Contact Us
    Completed
    Site KR00037
    Gwangju, Republic of Korea
    Contact Us
    Completed
    Site CN00057
    Tianjin, China
    Contact Us
    Completed
    Site CN00070
    Nanjing, China
    Contact Us
    Completed
    Site KR00035
    Seoul, Republic of Korea
    Contact Us
    Active, not recruiting
    Site CN00059
    Wuhan, China
    Contact Us
    Active, not recruiting
    Site TW00022
    Taichung, Taiwan, Province of China
    Contact Us
    Active, not recruiting
    Site CN00049
    Zhuzhou, China
    Contact Us
    Active, not recruiting
    Site CN00061
    Changchun, China
    Contact Us
    Completed
    Site KR00034
    Seoul, Republic of Korea
    Contact Us
    Active, not recruiting
    Site CN00052
    Guangzhou, China
    Contact Us
    Completed
    Site CN00074
    Jieyang, China
    Contact Us
    Completed
    Site CN00054
    Beijing, China
    Contact Us
    Active, not recruiting
    Site CN00063
    Guangzhou, China
    Contact Us
    Active, not recruiting
    Site CN00068
    Ningbo, China
    Contact Us
    Active, not recruiting
    Site KR00033
    Seoul, Republic of Korea
    Contact Us
    Active, not recruiting
    Site CN00075
    Pingxiang, China
    Contact Us
    Completed
    Site CN00073
    Zhengzhou, China
    Contact Us
    Completed
    Site TW00024
    Taichung, Taiwan, Province of China
    Contact Us
    Active, not recruiting
    Site CN00028
    Jilin, China
    Contact Us
    Completed
    Site TW00023
    Taichung, Taiwan, Province of China
    Contact Us
    Active, not recruiting
    Site CN00072
    Guangzhou, China
    Contact Us
    Completed
    Site CN00045
    Beijing, China
    Contact Us
    Active, not recruiting
    Site CN00066
    Qingdao, China
    Contact Us
    Active, not recruiting
    Site CN00058
    Inner Mongolia, China
    Contact Us
    Completed
    Site CN00032
    Changsha, China
    Contact Us
    Active, not recruiting
    Site CN00047
    Shantou, China
    Contact Us
    Active, not recruiting
    Site CN00064
    Jiujiang, China
    Contact Us
    Active, not recruiting
    Site CN00056
    Shanghai, China
    Contact Us
    Completed
    Site CN00048
    Anhui, China
    Contact Us
    Active, not recruiting
    Site CN00060
    Nanjing, China
    Contact Us
    Trial info
    Follow Trial
    Age
    18+ years
    Diamond icon
    Condition
  • Rheumatoid Arthritis
    • Gender icon
    Sex
    Female & Male
    Calendar icon
    Trial Dates
    Sep 2018 - Apr 2021
    Additional Study Details
    Inclusion Criteria
    • Subject is a man or woman and considered to be an adult, according to the local legal definition, at the time of informed consent.
    • Subject has RA diagnosed according to the 1987 American College of Rheumatology (ACR) criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria.
    • Subject did not receive the following drugs, or received the drugs with stable dosage for at least 28 days prior to the baseline (start of treatment) for RA treatment: Non-steroidal anti-inflammatory drugs (NSAIDs; excluding topical formulations), oral morphine or equivalent opioid analgesics (≤ 30 mg/day), acetaminophen, or oral corticosteroids (≤ 10 mg/day in prednisolone equivalent).
    • Subject has active RA as evidenced by both of the following:
      • ≥ 6 tender/painful joints (using 68-joint assessment)
      • ≥ 6 swollen joints (using 66-joint assessment)
    • Subject has CRP > 0.50 mg/dL. The re-test of CRP will be allowed, if the subject’s CRP value at the time of screening test is more than 0.30 mg/dL and also his/her most recent CRP value which was carried out up to 90 days before the date of screening test was more than 0.5 mg/dL.
    • Subject meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA Class I, II, or III.
    • Subject has inadequate response or intolerance for MTX.
    • For inadequate responder to MTX, subject has had regular use of MTX for at least 90 days prior to screening at a dose that, in accordance with local clinical practice, is considered acceptable to adequately assess clinical response. The dose of MTX must have been a stable, unchanging oral dose of 7.5 to 20 mg/week (or the equivalent injectable dose) for at least the 28 days prior to screening. Subject is able to continue stable dose of MTX from at least 28 days prior to screening until the end of the administration period of study drug.
    • For subject who is intolerant of MTX, subject has had regular use of the following DMARDs, and when the following DMARDs are concomitantly administered to subject, the drugs must be administered for at least 90 days prior to screening, and must be stable from at least 28 days prior to screening until the end of the administration period of study drug.
      • Hydroxychloroquine
      • Salazosulfapyridine
      • Gold
      • D-penicillamine
      • Lobenzarit
      • Actarit
      • Bucillamine
      • Iguratimod
    MaximizeExclusion Criteria
    • Subject has received a biologic DMARD within the specified period:
      • Anakinra: within 28 days prior to baseline
      • Etanercept: within 28 days prior to baseline
      • Adalimumab, infliximab: within 56 days prior to baseline
      • Golimumab, certolizumab pegol: within 70 days prior to baseline
      • Abatacept, tocilizumab: within 84 days prior to baseline
      • Denosumab: within 150 days prior to baseline
      • Rituximab: within 180 days prior to baseline
    • Subject has inadequate response to at least 3 biologic DMARDs.
    • Subject has received a non-biologic DMARD listed below or other drugs used in the treatment of RA within 28 days prior to baseline. Leflunomide is prohibited within 90 days prior to baseline. Alternatively, leflunomide is prohibited at least 28 days prior to baseline if washout with cholestyramine for at least 17 days is completed within 28 days prior to baseline. However, topical drugs other than those for the treatment of RA may be used concomitantly.
      • Leflunomide
      • Tacrolimus
      • Cyclosporine
      • Cyclophosphamide
      • Azathioprine
      • Minocycline
      • Mizoribine
    • Subject has received Chinese herbal medicines listed below or other herbal drugs used in the treatment of RA within 28 days prior to baseline.
      • Tripterygium wilfordii
      • Total glucosides of paeony
      • Tsuduranine
    • Subject has received tofacitinib, baricitinib or other JAK inhibitor (including other investigational drugs).
    • Subject has received intra-articular, intravenous, intramuscular, or endorectal (including suppositories for anal diseases) corticosteroid within 28 days prior to baseline.
    • Subject has participated in any study of ASP015K and has received ASP015K or placebo.
    • Subject has received other investigational drugs within 90 days or within 5 half-lives, whichever is longer, prior to baseline.
    • Subject has received plasma exchange therapy within 60 days prior to baseline.
    • Subject has undergone joint drainage, has received local anesthesia and nerve block, or has received articular cartilage protectant (such as glucosamine sulfate, chondroitin sulfate these DMORD medicine) at the assessed joint within 28 days prior to baseline.
    • Subject has undergone surgery and has residual effects in the assessed joints or is scheduled to undergo surgery that may affect the study evaluation of the assessed joints.
    • Subject is diagnosed as inflammatory arthritis (psoriatic arthritis, ankylosing spondylitis, SLE, sarcoidosis, etc.) other than RA.
    • Subject has any of the following laboratory values:
      • Hemoglobin < 9.0 g/dL
      • Absolute neutrophil count < 1000/μL
      • Absolute lymphocyte count < 800/μL
      • Platelet count < 75000/μL
      • Alanine aminotransferase (ALT) ≥ 2 × upper limit of normal (ULN)
      • Aspartate aminotransferase (AST) ≥ 2 × ULN
      • Total bilirubin (TBL) ≥ 1.5 × ULN
      • Estimated glomerular filtration rate (eGFR) ≤ 40 mL/min as measured by the MDRD method
      • β-D-glucan > ULN
    • Subject has a history of or concurrent active tuberculosis (TB). Eligibility criteria for TB are tabulated below:
    • Subject meets any of the following in terms of infection except for TB:
      • History of or concurrent severe herpes zoster (associated with Hunt syndrome or having ulcerative lesions) or disseminated herpes zoster
      • History of multiple recurrences (at least twice) of localized herpes zoster
      • Serious infection requiring hospitalization within 90 days prior to baseline
      • Subject has received intravenous antibiotics within 90 days prior to baseline. (However, prophylactic antibiotics are allowed.)
      • Subject with high risk of infection (e.g., subject with urinary catheter)
    • Subject has a history of or concurrent interstitial pneumonia and inappropriate to participate in this study.
    • Subject has a history of or concurrent malignant tumor (except for successfully treated basal cell carcinoma).
    • Subject has received live or live attenuated virus vaccination within 56 days prior to baseline. (Inactivated vaccines including influenza and pneumococcal vaccines are allowed.)
    • Subject has any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, infectious, or autoimmune disease except for RA (excluding Sjogren’s syndrome and chronic thyroiditis), or any ongoing illness which would make the subject unsuitable for the study.
    • Subject has a history of clinically significant allergy. (Clinically significant allergy includes allergies such as systemic urticaria induced by specific antigens and drugs, anaphylaxis, and allergy associated with shock necessitating hospitalized treatment.)
    • Subject has received medications that are CYP3A substrates with narrow therapeutic range within 14 days prior to baseline. These medications include: dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, temsirolimus, and disopyramide.
    • Subject has concurrent cardiac failure, defined as New York Heart Association (NYHA) classification Class III or higher, or a history of it.
    • Subject has concurrent prolonged QT syndrome or a history of it. Subject has prolonged QT interval (defined as QTc ≥ 500 msec. Subject has QTc ≥ 500 msec at retest will be excluded).
    • Subject has congenital short QT syndrome or a history of it. Subject has shortened QT interval (defined as QTc < 330 msec. Subject has QTc < 330 msec at retest will be excluded).
    • Subject has a history of positive HIV infection.
    • Female subject is pregnant or might be pregnant, is nursing, wishes to conceive for a period running from the time informed consent is given within 60 days after end of treatment, or for whom the possibility of pregnancy cannot be ruled out as a result of the serum pregnancy test given at the time of screening.
    • Male subject cannot practice at least 2 types of contraception from the time of informed consent to 90 days after end of treatment, or subject is a woman with childbearing potential who cannot practice at least 2 types of contraception from the time of informed consent to 60 days after end of treatment.
    • Male subject does not agree not to donate sperm starting at informed consent and through the treatment period and for at least 90 days after final study drug administration. Female subject who do not agree not to donate ova starting at informed consent through the treatment period and for 60 days after final study drug administration.
    • Subject has a history or complication of lymphatic diseases such as lymphoproliferative disorder, lymphoma, and leukemia.

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    Find a Trial
    2

    Why are Clinical Trials Important?

    Learn More
    3

    Why Participate in a Clinical Trial?

    Discover More